相似文献
1
Disease clearance in ulcerative colitis: Is the ultimate therapeutic target?
United European Gastroenterol J. 2023 Oct;11(8):717-719. doi: 10.1002/ueg2.12436. Epub 2023 Jul 3.
2
Crohn's & Colitis Australia inflammatory bowel disease audit: measuring the quality of care in Australia.
Intern Med J. 2019 Jul;49(7):859-866. doi: 10.1111/imj.14187.
3
Inflammatory Bowel Disease.
Prim Care. 2023 Sep;50(3):411-427. doi: 10.1016/j.pop.2023.03.009. Epub 2023 May 10.
4
Renal Manifestations in Inflammatory Bowel Disease: A Cohort Study During the Biologic Era.
Med Sci Monit. 2022 Jul 6;28:e936497. doi: 10.12659/MSM.936497.
5
Clinical presentation of Crohn's, ulcerative colitis, and indeterminate colitis: Symptoms, extraintestinal manifestations, and disease phenotypes.
Semin Pediatr Surg. 2017 Dec;26(6):349-355. doi: 10.1053/j.sempedsurg.2017.10.003. Epub 2017 Oct 5.
6
Identification and diagnosis of Crohn disease and ulcerative colitis in children.
J Paediatr Child Health. 2020 Nov;56(11):1731-1734. doi: 10.1111/jpc.14925. Epub 2020 May 29.
7
Extra-intestinal manifestations of inflammatory bowel diseases.
Pharmacol Res. 2020 Nov;161:105206. doi: 10.1016/j.phrs.2020.105206. Epub 2020 Sep 28.
8
Cancer in Inflammatory Bowel Disease.
Gastroenterol Clin North Am. 2022 Sep;51(3):649-666. doi: 10.1016/j.gtc.2022.05.003. Epub 2022 Aug 30.
9
[Inflammatory bowel disease: an overview].
Med Monatsschr Pharm. 2013 Nov;36(11):402-8; quiz 409.
10
Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America.
J Pediatr Gastroenterol Nutr. 2007 May;44(5):653-74. doi: 10.1097/MPG.0b013e31805563f3.
引用本文的文献
1
Anemoside B4 alleviates ulcerative colitis by attenuating intestinal oxidative stress and NLRP3 inflammasome via activating aryl hydrocarbon receptor through remodeling the gut microbiome and metabolites.
Redox Biol. 2025 Jun 28;85:103746. doi: 10.1016/j.redox.2025.103746.
2
Gut microbiota-derived butyrate mediates the anticolitic effect of indigo supplementation through regulating CD4 T cell differentiation.
Imeta. 2025 Apr 19;4(3):e70040. doi: 10.1002/imt2.70040. eCollection 2025 Jun.
3
Disease Clearance in Ulcerative Colitis: A Narrative Review.
United European Gastroenterol J. 2025 Jul;13(6):902-910. doi: 10.1002/ueg2.12714. Epub 2025 Apr 16.
4
Novel outcomes in inflammatory bowel disease.
J Crohns Colitis. 2025 Apr 4;19(4). doi: 10.1093/ecco-jcc/jjaf040.
5
Advancing Therapeutic Targets in IBD: Emerging Goals and Precision Medicine Approaches.
Pharmaceuticals (Basel). 2025 Jan 10;18(1):78. doi: 10.3390/ph18010078.
6
AI and endoscopy/histology in UC: the rise of machine.
Therap Adv Gastroenterol. 2024 Oct 18;17:17562848241275294. doi: 10.1177/17562848241275294. eCollection 2024.
7
Kuicolong-yu enema decoction retains traditional Chinese medicine enema attenuates inflammatory response ulcerative colitis through TLR4/NF-κB signaling pathway.
World J Gastrointest Surg. 2024 Apr 27;16(4):1149-1154. doi: 10.4240/wjgs.v16.i4.1149.
本文引用的文献
1
Emerging drugs for the treatment of moderately to severely active ulcerative colitis: review of phase II and III clinical trials.
Expert Opin Emerg Drugs. 2023 Mar;28(1):27-42. doi: 10.1080/14728214.2023.2186399. Epub 2023 Mar 7.
2
Going Beyond a Treat-To-Target to a Treat-To-Clear and a Treat-To-Trough Therapeutic Strategy in Patients with Inflammatory Bowel Disease?
J Crohns Colitis. 2023 Jun 16;17(6):825-826. doi: 10.1093/ecco-jcc/jjad014.
3
Efficacy and Safety of Dual Targeted Therapy for Partially or Non-responsive Inflammatory Bowel Disease: A Systematic Review of the Literature.
Dig Dis Sci. 2023 Jun;68(6):2604-2623. doi: 10.1007/s10620-023-07837-0. Epub 2023 Feb 20.
4
Ulcerative colitis: Impact of early disease clearance on long-term outcomes - A multicenter cohort study.
United European Gastroenterol J. 2022 Sep;10(7):775-782. doi: 10.1002/ueg2.12288. Epub 2022 Sep 15.
5
Breaking Through the Therapeutic Ceiling: What Will It Take?
Gastroenterology. 2022 Apr;162(5):1507-1511. doi: 10.1053/j.gastro.2021.09.078. Epub 2022 Jan 4.
6
Bimekizumab versus Secukinumab in Plaque Psoriasis.
N Engl J Med. 2021 Jul 8;385(2):142-152. doi: 10.1056/NEJMoa2102383. Epub 2021 Apr 23.
7
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD.
Gastroenterology. 2021 Apr;160(5):1570-1583. doi: 10.1053/j.gastro.2020.12.031. Epub 2021 Feb 19.
8
Transcriptional Signatures That Define Ulcerative Colitis in Remission.
Inflamm Bowel Dis. 2021 Jan 1;27(1):94-105. doi: 10.1093/ibd/izaa075.
9
Evolving therapeutic goals in ulcerative colitis: towards disease clearance.
Nat Rev Gastroenterol Hepatol. 2020 Jan;17(1):1-2. doi: 10.1038/s41575-019-0211-1.
10
Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial.
Lancet. 2019 Aug 17;394(10198):576-586. doi: 10.1016/S0140-6736(19)30952-3. Epub 2019 Jul 4.
Zotero 插件